Novo, Valo collaborate on treatments for cardiometabolic diseases using human data, AI

 Collaboration will apply Valo’s Opal Computational Platform™ and real-world patient dataset to enable the discovery and development of novel cardiometabolic drug programmes

Novo Nordisk licenses three preclinical drug discovery programmes in cardiovascular diseases discovered and developed by Valo using the Opal Computational Platform™

Valo will receive an upfront payment and a potential near-term milestone payment, totalling 60 million US dollars, and is eligible to receive milestone payments for up to 11 programmes, totalling up to 2.7 billion dollars, plus R&D funding and potential royalty payments

https://finance.yahoo.com/news/valo-health-novo-nordisk-collaborate-120000717.html